166 related articles for article (PubMed ID: 25141892)
41. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
42. A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Choi YH; Kim TW; Kim KP; Lee SS; Hong YS; Ryu MH; Lee JL; Chang HM; Ryoo BY; Kim HS; Shin JG; Kang YK
Oncology; 2012; 82(5):290-7. PubMed ID: 22555197
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
[TBL] [Abstract][Full Text] [Related]
44. Determinants of prognosis and response to therapy in colorectal cancer.
Iqbal S; Lenz HJ
Curr Oncol Rep; 2001 Mar; 3(2):102-8. PubMed ID: 11177741
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
46. Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.
Inoue Y; Miki C; Watanabe H; Hiro J; Toiyama Y; Ojima E; Nakatani K; Nobori T; Kusunoki M
Oncol Rep; 2006 Nov; 16(5):971-4. PubMed ID: 17016579
[TBL] [Abstract][Full Text] [Related]
47. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
[TBL] [Abstract][Full Text] [Related]
48. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Kanekiyo S; Hazama S; Kondo H; Nagashima A; Eto R; Yoshida S; Shimizu R; Araki A; Yamamoto T; Uchiyama T; Yoshino S; Okayama N; Hinoda Y; Oka M
Anticancer Res; 2013 Aug; 33(8):3423-30. PubMed ID: 23898114
[TBL] [Abstract][Full Text] [Related]
49. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
50. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
[TBL] [Abstract][Full Text] [Related]
51. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
52. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
53. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Schulz C; Boeck S; Heinemann V; Stemmler HJ
Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
55. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
[TBL] [Abstract][Full Text] [Related]
57. A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Kim KP; Hong YS; Lee JL; Bae KS; Kim HS; Shin JG; Lee JS; Kim TW
Oncology; 2015; 88(3):164-72. PubMed ID: 25427841
[TBL] [Abstract][Full Text] [Related]
58. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Gold HT; Hall MJ; Blinder V; Schackman BR
Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
[TBL] [Abstract][Full Text] [Related]
59. Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Rawlley B; Diab O; Al-Rajabi R; Carroll E; Melancon T; Kasi A
Pharmacogenomics; 2020 Dec; 21(18):1265-1269. PubMed ID: 33203301
[No Abstract] [Full Text] [Related]
60. Colorectal cancer chemotherapy: irinotecan.
Rougier P; Mitry E
Semin Oncol; 2000 Oct; 27(5 Suppl 10):138-43. PubMed ID: 11049046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
